Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) issued its quarterly earnings data on Monday. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.20, FiscalAI reports.

Zentalis Pharmaceuticals Stock Up 3.4%

ZNTL opened at $1.80 on Wednesday. Zentalis Pharmaceuticals has a twelve month low of $1.25 and a twelve month high of $6.95. The company has a 50-day simple moving average of $2.66 and a 200 day simple moving average of $3.40. The stock has a market capitalization of $129.01 million, a price-to-earnings ratio of -0.94 and a beta of 1.91.

Insider Transactions at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters bought 4,335,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the transaction, the insider owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This represents a 32.09% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ZNTL shares. Rodman & Renshaw began coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, October 19th. Mizuho began coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target for the company. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $5.00 to $6.00 in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments. Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.